New Cell Pathway For Triggering Immune System Response Discovered

October 02, 1997

MEMPHIS, Tenn., October 3, 1997 -- New cancer treatments could result from the discovery reported today in Science of a pathway in blood cells through which signals triggering the immune system response may be transmitted from the lymphocyte cell surface to its nucleus.

In making the discovery, researchers at St. Jude Children's Research Hospital located a new protein receptor on the lymphocyte cell surface, identifying it as a member of the important Tumor Necrosis Factor Receptor superfamily, members of which have become targets of a growing number of promising cancer treatments.

Receptors are molecules, often proteins, located on the surface of the cell that recognize and bind with specific molecules outside the cell, transmitting a signal to the interior of the cell.

The new receptor, called TACI (transmembrane activator and CAML-interactor), was also found by the researchers to interact physically with a protein inside the cell, called CAML (calcium-modulator and cyclophilin ligand). CAML, discovered by St. Jude researchers in 1994, triggers an influx of calcium which the cell nucleus reads as a key signal required for initiating the early immune response.

"Our research began with the observation that use of the transplant rejection inhibitor drug cyclosporin, used in bone marrow transplants for leukemia patients, blocked a calcium dependent signal from the T-cell receptor responsible for T-cell activation. Essentially working from the lymphocyte nucleus outward we first discovered CAML, then TACI and that TACI is part of the Tumor Necrosis Factor Receptor superfamily," said Richard Bram, M.D., Ph.D., leader of the St. Jude research team.

"We believe that these two proteins, acting in concert, help instruct lymphocytes to proceed with the program of cell activation and division. Abnormal expression or function of these proteins may contribute to the growth of leukemia cells, which are lymphocytes that grow inappropriately. Now, we are in a position to use knowledge of this signaling pathway to begin to look for more effective cancer treatments, particularly for leukemia and lymphoma patients, many of whom are children," added Bram.

St. Jude Children's Research Hospital, in Memphis, Tenn., was founded by the late entertainer Danny Thomas. The hospital is an internationally recognized biomedical research center dedicated to finding cures for catastrophic diseases of childhood. The hospital's work is primarily supported through funds raised by the American Lebanese Syrian Associated Charities (ALSAC). All St. Jude patients are treated regardless of their ability to pay. ALSAC covers all costs of treatment beyond those reimbursed by third party insurers, and total costs for families who have no insurance.

St. Jude Children's Research Hospital

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to